Bioactivity | Mycophenolic acid-13C17 (Mycophenolate-13C17) is the 13C labeled Mycophenolic acid (HY-B0421)[1]. Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 μM.?Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects[2][3]. |
Target | Mycophenolic acid (MPA) is an immunosuppressant drug used to prevent rejection in organ transplantation. It inhibits an enzyme needed for the growth of T cells and B cells. Mycophenolic acid (MPA) did not block the initial phase of viral translation but did interfere with viral protein synthesis in the amplification phase. Quantitative RT-PCR demonstrated that MPA prevented the accumulation of viral positive- and negative-strand RNA as the infection proceeded. Mycophenolic acid (MPA) inhibits flavivirus infection by preventing synthesis and accumulation of viral RNA. The effects of Mycophenolic acid (MPA) on DEN replication in monkey kidney (LLC-MK2) cells were examined. MPA (IC50=0.4+/-0.3 microM) inhibited DEN2 replication. Quantitative real-time RT-PCR of viral RNA and plaque assays of virions from DEN2-infected and Mycophenolic acid (MPA) (10 microM) -treated cells showed a fivefold increase in defective viral RNA production by cells treated with each drug. suggesting that one mode of antiviral action of MPA is by inhibition of inosine monophosphate dehydrogenase and thereby depletion of the intracellular GTP pool. |
Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。Mycophenolic acid 对多种 RNA 病毒具有抗病毒作用,包括流感、登革热病毒、寨卡病毒、轮状病毒、CCHFV 和汉坦病毒[2]。IMPDH 是鸟苷核苷酸从头合成中的限速酶[3]。Mycophenolic acid (0.01-1 μM; 72 小时) 对内皮细胞和成纤维细胞表现出优先的抗增殖活性。内皮细胞是对霉酚酸处理最敏感的细胞,其抗有丝分裂作用的 IC501 μM。U87 胶质母细胞瘤细胞对高达 1 μM 的 MPA 处理具有抗性[3]。Mycophenolic acid(0.05-2 μM;18 小时)表现出剂量依赖性下调 HDAC2 和 MYC,同时上调 NDRG1 水平[4]。 |
Name | Mycophenolic acid-13C17 |
CAS | 1202866-92-9 |
Formula | 13C17H20O6 |
Molar Mass | 337.21 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |